Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to DiffuseSandbox, its self-serve protein ...

By adding AI-enabled RNA design and active learning, Eclipsebio extends its sequencing-based analytics platform into a fully ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...

AI systems are only as fair and safe as the data they’re built on. While conversations about AI ethics often focus on model architecture, algorithmic transparency or deployment oversight, fairness and ...

Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...

For many years, the landscape of data center innovation has been dominated by solid-state electronics. The relentless pursuit of faster chips, denser racks and larger facilities has been the mantra ...